Large-vessel vasculitis
- PMID: 40939604
- DOI: 10.1016/S0140-6736(25)01436-9
Large-vessel vasculitis
Abstract
Primary large-vessel vasculitis encompasses conditions that, despite sharing many common features, constitute distinct entities that have their own prognostic implications. These conditions include giant cell arteritis and Takayasu arteritis, with isolated aortitis being increasingly recognised in the literature and studied within this disease spectrum. Epidemiological studies have evidenced a worldwide distribution of Takayasu arteritis. In giant cell arteritis, distinct clinical phenotypes with specific outcomes (ie, cranial and large vessel forms) have been recognised. The advancements that have been made in vascular imaging have enabled improvement in diagnosis and classification of these diseases, although their value in follow-up continues to be assessed. Targeted therapies that can induce clinical remission with reduced glucocorticoid exposure are emerging. However, many patients develop vascular damage over time, highlighting the need for further understanding of the pathophysiological link between inflammation, vascular injury, and remodelling.
© 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
Conflict of interest statement
Declaration of interests CAL declares research funding from Bristol-Myers Squibb, AstraZeneca, GlaxoSmithKline, and NS Pharma; and is a non-paid consultant for Bristol-Myers, AbbVie, and AstraZeneca. ZTM declares research funding and having consulted for Novartis, AstraZeneca, Abbvie, and Janssen. DS declares research funding and consulting for Novartis, Abbvie, Janssen, Fresenius, Roche-Chugai, and GlaxoSmithKline. All other authors declare no competing interests.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
